Brain Tissue Damage Induced by Multimodal Neuromonitoring In Situ during MRI after Severe Traumatic Brain Injury: Incidence and Clinical Relevance.
Daniel PinggeraPaul RhombergRonny BeerClaudius ThoméOndra PetrPublished in: Journal of clinical medicine (2022)
Both neuromonitoring and early magnetic resonance imaging (MRI) provide crucial information for treatment management and prognosis in patients with severe traumatic brain injury (sTBI). So far, neuromonitoring in situ impedes the routine implementation of MRI due to safety concerns. We aimed to evaluate the brain tissue damage induced by inserted neuromonitoring devices and its clinical relevance. Nineteen patients with sTBI and being exposed to at least one MRI with neuromonitoring in situ and one follow-up MRI after neuromonitoring removal were analyzed. All MRIs were reviewed for specific tissue damage. Three females and sixteen males (aged 20-74 years, mean 42.8 years) with an initial median GCS of 5 (range 3-8) were analyzed. No lesion was observed in six patients (31.6%), whereas another six patients (31.6%) demonstrated a detectable probe trajectory. Probe-related tissue damage was visible in seven patients (36.8%) with the size of the lesion prone to further enlarge with increasing cumulative duration of MRI examinations. Upon interdisciplinary evaluation, the lesions were not considered clinically relevant. Neuromonitoring probes in situ during MRI examinations may cause local brain tissue damage, yet without any clinical implications if placed correctly. Therefore, indications must be strictly based on joint decision from all involved disciplines.
Keyphrases
- magnetic resonance imaging
- contrast enhanced
- severe traumatic brain injury
- diffusion weighted imaging
- oxidative stress
- end stage renal disease
- ejection fraction
- computed tomography
- newly diagnosed
- traumatic brain injury
- peritoneal dialysis
- primary care
- white matter
- prognostic factors
- healthcare
- resting state
- cerebral ischemia
- fluorescence imaging
- brain injury
- patient reported
- single molecule
- fluorescent probe